183 related articles for article (PubMed ID: 35955836)
1. c-Kit Induces Migration of Triple-Negative Breast Cancer Cells and Is a Promising Target for Tyrosine Kinase Inhibitor Treatment.
López-Mejía JA; Tallabs-Utrilla LF; Salazar-Sojo P; Mantilla-Ollarves JC; Sánchez-Carballido MA; Rocha-Zavaleta L
Int J Mol Sci; 2022 Aug; 23(15):. PubMed ID: 35955836
[TBL] [Abstract][Full Text] [Related]
2. RON and MET Co-overexpression Are Significant Pathological Characteristics of Poor Survival and Therapeutic Targets of Tyrosine Kinase Inhibitors in Triple-Negative Breast Cancer.
Weng TH; Yao MY; Xu XM; Hu CY; Yao SH; Liu YZ; Wu ZG; Tang TM; Fu PF; Wang MH; Yao HP
Cancer Res Treat; 2020 Jul; 52(3):973-986. PubMed ID: 32324988
[TBL] [Abstract][Full Text] [Related]
3. The three receptor tyrosine kinases c-KIT, VEGFR2 and PDGFRα, closely spaced at 4q12, show increased protein expression in triple-negative breast cancer.
Jansson S; Bendahl PO; Grabau DA; Falck AK; Fernö M; Aaltonen K; Rydén L
PLoS One; 2014; 9(7):e102176. PubMed ID: 25025175
[TBL] [Abstract][Full Text] [Related]
4. Dual-target MDM2/MDMX inhibitor increases the sensitization of doxorubicin and inhibits migration and invasion abilities of triple-negative breast cancer cells through activation of TAB1/TAK1/p38 MAPK pathway.
Fan Y; Li M; Ma K; Hu Y; Jing J; Shi Y; Li E; Dong D
Cancer Biol Ther; 2019; 20(5):617-632. PubMed ID: 30462562
[TBL] [Abstract][Full Text] [Related]
5. Fibroblast-secreted hepatocyte growth factor mediates epidermal growth factor receptor tyrosine kinase inhibitor resistance in triple-negative breast cancers through paracrine activation of Met.
Mueller KL; Madden JM; Zoratti GL; Kuperwasser C; List K; Boerner JL
Breast Cancer Res; 2012 Jul; 14(4):R104. PubMed ID: 22788954
[TBL] [Abstract][Full Text] [Related]
6. Multi-targeted kinase inhibition alleviates mTOR inhibitor resistance in triple-negative breast cancer.
He J; McLaughlin RP; van der Noord V; Foekens JA; Martens JWM; van Westen G; Zhang Y; van de Water B
Breast Cancer Res Treat; 2019 Nov; 178(2):263-274. PubMed ID: 31388935
[TBL] [Abstract][Full Text] [Related]
7. FRET biosensor-based kinase inhibitor screen for ERK and AKT activity reveals differential kinase dependencies for proliferation in TNBC cells.
He J; Wink S; de Bont H; Le Dévédec S; Zhang Y; van de Water B
Biochem Pharmacol; 2019 Nov; 169():113640. PubMed ID: 31536726
[TBL] [Abstract][Full Text] [Related]
8. The non-receptor tyrosine kinase TNK2/ACK1 is a novel therapeutic target in triple negative breast cancer.
Wu X; Zahari MS; Renuse S; Kelkar DS; Barbhuiya MA; Rojas PL; Stearns V; Gabrielson E; Malla P; Sukumar S; Mahajan NP; Pandey A
Oncotarget; 2017 Jan; 8(2):2971-2983. PubMed ID: 27902967
[TBL] [Abstract][Full Text] [Related]
9. A novel orally available seleno-purine molecule suppresses triple-negative breast cancer cell proliferation and progression to metastasis by inducing cytostatic autophagy.
Chang CH; Bijian K; Wernic D; Su J; da Silva SD; Yu H; Qiu D; Asslan M; Alaoui-Jamali MA
Autophagy; 2019 Aug; 15(8):1376-1390. PubMed ID: 30773992
[TBL] [Abstract][Full Text] [Related]
10. STAT3-induced NCK1 elevation promotes migration of triple-negative breast cancer cells via regulating ERK1/2 signaling.
He P; Sheng J; Qi J; Bai X; Li J; Wang F; Yuan Y; Zheng X
Mol Biol Rep; 2022 Jan; 49(1):267-278. PubMed ID: 34846647
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic activity of DCC-2036, a novel tyrosine kinase inhibitor, against triple-negative breast cancer patient-derived xenografts by targeting AXL/MET.
Shen Y; Zhang W; Liu J; He J; Cao R; Chen X; Peng X; Xu H; Zhao Q; Zhong J; Ding W; Lei X; Jiang Y; Zu X
Int J Cancer; 2019 Feb; 144(3):651-664. PubMed ID: 30289981
[TBL] [Abstract][Full Text] [Related]
12. PRKCQ promotes oncogenic growth and anoikis resistance of a subset of triple-negative breast cancer cells.
Byerly J; Halstead-Nussloch G; Ito K; Katsyv I; Irie HY
Breast Cancer Res; 2016 Sep; 18(1):95. PubMed ID: 27663795
[TBL] [Abstract][Full Text] [Related]
13. Strictinin, a novel ROR1-inhibitor, represses triple negative breast cancer survival and migration via modulation of PI3K/AKT/GSK3ß activity.
Fultang N; Illendula A; Chen B; Wu C; Jonnalagadda S; Baird N; Klase Z; Peethambaran B
PLoS One; 2019; 14(5):e0217789. PubMed ID: 31150511
[TBL] [Abstract][Full Text] [Related]
14. GSK3β regulates epithelial-mesenchymal transition and cancer stem cell properties in triple-negative breast cancer.
Vijay GV; Zhao N; Den Hollander P; Toneff MJ; Joseph R; Pietila M; Taube JH; Sarkar TR; Ramirez-Pena E; Werden SJ; Shariati M; Gao R; Sobieski M; Stephan CC; Sphyris N; Miura N; Davies P; Chang JT; Soundararajan R; Rosen JM; Mani SA
Breast Cancer Res; 2019 Mar; 21(1):37. PubMed ID: 30845991
[TBL] [Abstract][Full Text] [Related]
15. Targeting Receptor Tyrosine Kinases as a Novel Strategy for the Treatment of Triple-Negative Breast Cancer.
Jaradat SK; Ayoub NM; Al Sharie AH; Aldaod JM
Technol Cancer Res Treat; 2024; 23():15330338241234780. PubMed ID: 38389413
[TBL] [Abstract][Full Text] [Related]
16. HSulf‑1 and palbociclib exert synergistic antitumor effects on RB‑positive triple‑negative breast cancer.
Chen F; Zhang Z; Yu Y; Liu Q; Pu F
Int J Oncol; 2020 Jul; 57(1):223-236. PubMed ID: 32377705
[TBL] [Abstract][Full Text] [Related]
17. Pharmacotranscriptomic profiling of resistant triple-negative breast cancer cells treated with lapatinib and berberine shows upregulation of PI3K/Akt signaling under cytotoxic stress.
Jabbarzadeh Kaboli P; Luo S; Chen Y; Jomhori M; Imani S; Xiang S; Wu Z; Li M; Shen J; Zhao Y; Wu X; Hin Cho C; Xiao Z
Gene; 2022 Mar; 816():146171. PubMed ID: 35026293
[TBL] [Abstract][Full Text] [Related]
18. The tyrosine kinase inhibitor nintedanib activates SHP-1 and induces apoptosis in triple-negative breast cancer cells.
Liu CY; Huang TT; Chu PY; Huang CT; Lee CH; Wang WL; Lau KY; Tsai WC; Chao TI; Su JC; Chen MH; Shiau CW; Tseng LM; Chen KF
Exp Mol Med; 2017 Aug; 49(8):e366. PubMed ID: 28798401
[TBL] [Abstract][Full Text] [Related]
19. Combinatorial inhibition of PTPN12-regulated receptors leads to a broadly effective therapeutic strategy in triple-negative breast cancer.
Nair A; Chung HC; Sun T; Tyagi S; Dobrolecki LE; Dominguez-Vidana R; Kurley SJ; Orellana M; Renwick A; Henke DM; Katsonis P; Schmitt E; Chan DW; Li H; Mao S; Petrovic I; Creighton CJ; Gutierrez C; Dubrulle J; Stossi F; Tyner JW; Lichtarge O; Lin CY; Zhang B; Scott KL; Hilsenbeck SG; Sun J; Yu X; Osborne CK; Schiff R; Christensen JG; Shields DJ; Rimawi MF; Ellis MJ; Shaw CA; Lewis MT; Westbrook TF
Nat Med; 2018 May; 24(4):505-511. PubMed ID: 29578538
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of Akt/mTOR pathway overcomes intrinsic resistance to dasatinib in triple-negative breast cancer.
Haga Y; Higashisaka K; Yang L; Sekine N; Lin Y; Tsujino H; Nagano K; Tsutsumi Y
Biochem Biophys Res Commun; 2020 Dec; 533(4):672-678. PubMed ID: 33036754
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
